Outpace Bio

Outpace Bio is a private, pre-clinical stage biotech pioneering AI-driven protein design to develop next-generation cell therapies for solid tumors. The company's platform creates novel, fully human protein functions to address multiple failure points in current treatments, including immunosuppressive tumor microenvironments, poor T-cell persistence, and lack of specificity. By integrating its modular technology suite (OUTSMART™, OUTLAST™, OUTSPACER™, OUTSAFE™, and logic gating) into cell therapies, Outpace aims to build curative products for a broad range of cancers that are currently untreatable with existing cell therapy approaches.

AI-powered protein design platform that creates novel, fully human protein functions to program cell therapies. The modular platform includes technologies for optimized CAR spacing (OUTSPACER™), designed cytokines (OUTSMART™), T-cell persistence (OUTLAST™), safety switches (OUTSAFE™), and logic-gated targeting.

Outpace operates in the highly competitive field of next-generation cell therapy for solid tumors, competing with companies developing armored CAR-Ts, cytokine engineering, logic gates, and synthetic biology platforms. Key differentiators are its focus on fully human, AI-designed novel protein functions (beyond natural protein engineering) and its integrated, modular approach to solving multiple barriers simultaneously.